Korro Bio, Inc. (KRRO)
| Market Cap | 114.23M |
| Revenue (ttm) | 7.37M |
| Net Income (ttm) | -88.42M |
| Shares Out | 9.42M |
| EPS (ttm) | -9.42 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100,911 |
| Open | 11.74 |
| Previous Close | 12.10 |
| Day's Range | 11.68 - 12.21 |
| 52-Week Range | 5.20 - 55.89 |
| Beta | 2.44 |
| Analysts | Strong Buy |
| Price Target | 47.10 (+288.29%) |
| Earnings Date | Mar 17, 2026 |
About KRRO
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. Its lead product candidate is KRRO-110 which is in Phase 1/2 clinical trial for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson’s... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for KRRO stock is "Strong Buy." The 12-month stock price target is $47.1, which is an increase of 288.29% from the latest price.
News
Korro to Present at the TD Cowen 46th Annual Health Care Conference
CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and hi...
Korro Bio, Inc. (KRRO) Analyst/Investor Day Transcript
Korro Bio, Inc. (KRRO) Analyst/Investor Day Transcript
Korro Bio, Inc. (KRRO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Korro Bio, Inc. (KRRO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Korro to Host Virtual Analyst Day on January 27, 2026
- Program to feature presentations from the company management about KRRO-121 for the potential treatment of hyperammonemia , a leading clinical hepatologist about ammonia-driven diseases, and a care...
Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the 44th Annual...
Korro Bio Early Trial Results Fall Short; Stock Hits New Low
Korro Bio, Inc. (NASDAQ: KRRO) stock is sinking on Thursday with a session volume of 6.68 million compared to the average volume of 1.42 million, as per data from Benzinga Pro.
This biotech is halting its work with Novo Nordisk and laying off more people
Korro is the latest to rethink its ties with the Danish pharma company.
Korro Reports Third Quarter Financial Results, Provides Updates on KRRO-110 in Alpha-1 Antitrypsin Deficiency and Additional Pipeline Programs
CAMBRIDGE, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- — KRRO-110 produced functional protein in Alpha-1 Antitrypsin Deficiency (AATD) patients — KRRO-110 did not reach projected levels of functional...
Korro to Participate in Upcoming Investor and Scientific Conferences
CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor and scientifi...
Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates
— Interim readout from Phase 1/2a REWRITE clinical trial of KRRO-110 on track for the second half of 2025 — Completed dosing of over 80% of planned REWRITE healthy volunteers across multiple single as...
Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110
CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on e...
Korro to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor conferences: 20...
Korro Reports First Quarter 2025 Financial Results and Provides Business Updates
CAMBRIDGE, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on ed...
Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer
Strengthens leadership team with additional key appointment of GaoZhong Zhu, Ph.D. as Senior Vice President of Chemistry, Manufacturing and Controls (CMC) & Technical Operations and promotion of Olive...
Korro Reports Full Year 2024 Financial Results and Provides Business Updates
CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on ...
KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency
CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on ...
Korro to Present at the TD Cowen 45th Annual Health Care Conference
CAMBRIDGE, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on e...
Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency
-REWRITE study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of KRRO-110
Korro to Present at the Jefferies London Healthcare Conference
CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for b...
Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board
-Regulatory filing of Phase 1/2 clinical study for Alpha-1 Antitrypsin Deficiency (AATD) submitted to Australian Bellberry Human Research Ethics Committee (HREC)
Korro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society
CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for ...
Korro to Participate in Upcoming September Investor and Scientific Conferences
CAMBRIDGE, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for b...
Korro Reports Second Quarter 2024 Financial Results and Provides Business Updates
CAMBRIDGE, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for ...
Korro to Participate in Upcoming June Investor and Scientific Conferences
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor and scientific ...
Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference
CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly ...